All products Quality & compliance Resources About Contact
Request a quote

Regulatory

CEP, USDMF or both? Matching the documentation pack to the destination market

The same API needs different paperwork in Europe, the United States and an emerging market. Here is how the three main routes differ, and where buyers over-specify.

Published 2026-11-06 · Bioran Pharma technical desk

Needle-like crystals of an organic compound under amber laboratory light
Crystalline form under polarised-style light — illustrative photography

Buyers routinely ask for "CEP and DMF" as a single line item in a quotation request. These are different instruments serving different regulators, and asking for both is sometimes right and sometimes a way of paying for a document nobody will read.

CEP — Certificate of Suitability (Europe)

Issued by the EDQM, a CEP certifies that the substance described in a pharmacopoeial monograph is manufactured in a way that controls the impurities the monograph does not cover. Your formulation partner references the CEP number in the marketing authorisation dossier instead of submitting a full drug-substance section.

  • What it saves you: the entire open and closed part of the API section in an EU filing.
  • What it costs you: dependence on the certificate holder keeping it current. A suspended CEP stops your filing.
  • When to insist on it: any EU marketing authorisation, including a decentralised or mutual-recognition procedure.

USDMF — Drug Master File (United States)

A Type II DMF is a confidential submission to the FDA describing facilities, process, characterisation and stability of the drug substance. It is not approved or rejected — it is reviewed only when an applicant references it in an ANDA or NDA.

  • What it saves you: duplicating detailed manufacturing information in your own application.
  • What it costs you: the DMF must be current and the holder must authorise your reference in writing; an inactive or outdated DMF creates a review delay you cannot fix yourself.
  • When to insist on it: any US filing, including a 505(b)(2) pathway.

Neither — emerging and semi-regulated markets

Many markets accept a pharmacopoeial-grade product with a full CoA, a GMP certificate for the site and a site master file, without a CEP or a US DMF. Over-specifying here is a real cost: a supplier who holds a CEP prices it into the quotation whether or not you need it.

Practical rule: specify the market of release first, then the document. A quotation that names the market and the filing route gets a materially different price from one that says "full documentation required".

What to write in the enquiry

Three sentences are enough:

  • The destination market and the filing route (e.g. "EU, decentralised procedure, generic").
  • The pharmacopoeial monograph and grade you need.
  • Whether you need the CEP reference number, the DMF open part under a confidentiality agreement, or both.

With those three facts, a supplier can tell you honestly whether they can support the filing or whether you should look elsewhere — which is the most useful answer you can get in the first exchange.


This note describes general industry practice. It is not regulatory advice and does not replace the requirements of your destination authority or your own quality system.

Back to all resources

Need a specification, a sample or a price?

Send the CAS number, the grade your dossier requires and the annual volume. You will get a technical reply from the product desk — not a sales autoresponder.